July 25, 2016 12:56 AM ET


Company Overview of MaxCyte, Inc.

Key Executives for MaxCyte, Inc.

NameBoard RelationshipsTitleAge
Douglas Arthur Doerfler 120 RelationshipsCo-Founder, Chief Executive Officer, President, Director and Member of Nominations Committee60
Ronald Evan Holtz CPA6 RelationshipsChief Financial Officer, Secretary and Director58
Madhusudan Viswanath Peshwa Ph.D.1 RelationshipsChief Scientific Officer and Executive Vice President of Cellular Therapies48

MaxCyte, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
J. Stark Thompson Ph.D. 12 RelationshipsOre Holdings, Inc74
Douglas Arthur Doerfler 120 RelationshipsMaxCyte, Inc.60
Ronald Evan Holtz CPA 6 RelationshipsMaxCyte, Inc.58
William W. Brooke J.D. 31 RelationshipsWallace, Jordan, Ratcliff & Brandt59
Arthur Michael Mandell 23 RelationshipsPrestwick Pharmaceuticals, Inc.63
View All Board Members

MaxCyte, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee J.D.William W. Brooke31 Relationships2 Executives
Compensation Committee Ph.D.J. Stark Thompson12 Relationships3 Executives
Nominating Committee Arthur Michael Mandell23 Relationships3 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Total Short Term Compensation
Total Value of Options
Compensation as of Fiscal Year
MaxCyte, Inc. CEO Compensation
Industry Average


Cleveland BioLabs, Inc. Announces Executive Changes
July 22, 2016 8:22 PM ET
TetraLogic Pharmaceuticals Corporation Announces Resignation of Douglas Reed as M. D, Effective July 21, 2016
July 22, 2016 8:18 PM ET
ContraFect Corporation Appoints Steven C. Gilman as President and Chief Executive Officer
July 21, 2016 9:32 PM ET
William R. Ringo Intends to Resign from Mirati Therapeutics, Inc.'s Board of Directors
July 21, 2016 8:03 PM ET
Biostage Appoints Harout Dersimonian as Chief Scientific Officer to Oversee Cell Biology, Materials Science and Other Research Underlying its Organ Implant Development
July 21, 2016 12:56 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MaxCyte, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.